<DOC>
	<DOCNO>NCT02172196</DOCNO>
	<brief_summary>The objective investigate whether drug-drug interaction BI 10773 sitagliptin co-administered multiple oral dos . Therefore , relative bioavailabilities BI 10773 sitagliptin determine drug give combination compare BI 10773 sitagliptin give alone .</brief_summary>
	<brief_title>Bioavailability BI 10773 Sitagliptin Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Healthy male volunteer accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age 18 50 year ( incl . ) BMI 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation Any finding medical examination deviate normal clinical relevance . Repeated measurement systolic blood pressure great 140 mm Hg diastolic blood pressure great 90 mm Hg Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug within one month le 10 halflives respective drug prior first study drug administration except relevant interaction rule Participation another trial investigational drug within two month prior first study drug administration Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( average consumption 30 g/day ) Drug abuse Blood donation ( 100 mL within four week prior start study ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor TdP ( Torsades de pointes ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>